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Exclusive breastfeeding (EBF)—giving infants only breast-milk (and medications, vitamins or oral rehydration solution (ORS) as needed) for the first 6 months of life—is effective in prevent-
ing deaths from diarrhoea, pneumonia and other leading causes of 
child mortality1–4. Breast-milk has been characterized as a ‘person-
alized medicine’ for infants2 due to its nutritional properties, natu-
ral growth stimulators and tailored immune-protective properties, 
which collectively contribute to infant growth, development and 
survival5–8. Furthermore, evidence suggests long-term health ben-
efits of breastfeeding, including reduced risks of cardiovascular 
diseases and increased benefits to human capital in adulthood2,9,10. 
The introduction of supplementary food and water during the first 
6 months of life, particularly in settings lacking reliable access to 
clean water, can expose infants to infections from a range of patho-
gens1,3. Along with the initiation of breastfeeding within the first 
hour after birth and continued breastfeeding to 2 years, the World 
Health Organization (WHO) considers EBF to be an optimal 
breastfeeding practice11 and included it as a proven protective inter-
vention in the Global Action Plan for Pneumonia and Diarrhoea 
(GAPPD)1. Despite the benefits, the proportion of exclusively 
breastfed children remains low in many low- and middle-income 
countries (LMICs), where most child deaths attributed to subop-
timal breastfeeding occur12. Accelerated uptake in EBF is required 
to successfully achieve the World Health Organization’s Global 
Nutrition Target (WHO GNT) of at least 50% EBF prevalence by 
202511 and the recently updated WHO GNT of at least 70% EBF 
prevalence by 203013.
This study is a part of a body of work mapping 
high-spatial-resolution estimates to track progress toward the 
WHO GNTs14–17. Building on our previous geospatial analysis of 
EBF prevalence in sub-Saharan Africa14, we synthesized data from 
349 geo-referenced household surveys from years 1998 to 2018 rep-
resenting 302,435 infants under 6 months to produce annual 2000–
2018 subnational estimates for the proportion and absolute number 
of exclusively breastfed infants for 94 LMICs. We used 14 geograph-
ically distinct modelling regions which were determined on the 
basis of epidemiological homogeneity and geographical contiguity 
by the Global Burden of Disease (GBD) study18 (Supplementary 
Table 4 and Supplementary Fig. 7). We first mapped estimates on 
a 5 × 5-km grid to align with the resolution of many of the covari-
ates used in this study and then aggregated to more policy-relevant 
second- and first-administrative-level units for each country in our 
analysis. Here we provide mapped annual estimates of EBF preva-
lence and trends at policy-relevant administrative and national lev-
els from 2000 to 2018, as well as the estimated number of infants not 
receiving EBF. On the basis of trends in the most recent years, we 
project these estimates to the years 2025 and 2030, and determine 
the probability of meeting the WHO GNTs of ≥50% and ≥70% EBF 
prevalence in the respective target years. Furthermore, we exam-
ine relative and absolute subnational inequalities of EBF prevalence 
within LMICs and compare areas with low EBF prevalence to areas 
with high disease burden and low coverage of mitigating interven-
tions. The full array of our model outputs—at various spatial levels 
and aggregations—is available through an online visualization tool 
(https://vizhub.healthdata.org/lbd/ebf), with additional results in 
the Supplementary Information.
Results
Regional, national and subnational trends in EBF prevalence. 
EBF prevalence varied widely between and within LMICs from 
2000 to 2018 (Fig. 1a,b). General increases in mean EBF prevalence 
occurred across LMICs over the study period, from 28.6% (95% 
uncertainty interval: 22.9–35.4%) in 2000 to 38.7% (28.3–49.9%) 
in 2018. Regionally, most LMICs in Andean South America, South 
Asia and East Asia had relatively high EBF levels throughout the 
study period; for example, Peru (63.6% (60.9–66.4%) in 2000; 
69.2% (57.6–79.1%) in 2018), Nepal (64.2% (49.1–76.9%) in 2000; 
64.5% (53.6–74.3%) in 2018) and Mongolia (51.9% (49.3–54.4%) 
in 2000; 55.1% (52.1–58.1%) in 2018) all maintained high national 
EBF prevalence. Several countries in other regions maintained low 
EBF prevalence throughout the study, including the Dominican 
Republic (13.2% (9.7–17.8%) in 2000; 8.2% (4.7–14.3%) in 2018), 
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Suriname (6.4% (4.3–9.2%); 5.7% (3.2–9.6%)), Tunisia (10.9% (6.7–
17.0%); 12.2% (7.7–18.0%)), Yemen (11.7% (4.7–22.3%); 12.5% 
(7.3–20.2%)) and Thailand (7.5% (4.9–11.1%); 13.9% (9.8–19.0%)). 
National 2018 EBF levels varied broadly between countries in the 
regions of Central America and the Caribbean (8.2% (4.7–14.3%) 
in the Dominican Republic; 50.7% (40.3–61.7%) in Guatemala), 
Tropical South America (5.7% (3.2–9.6%) in Suriname; 32.4% 
(29.1–35.8%) in Paraguay), Central Asia (18.7% (13.9–24.7%) in 
Uzbekistan; 51.8% (44.9–58.8%) in Afghanistan), Southeast Asia 
(13.9% (9.8–19.0%) in Thailand; 62.0% (50.4–72.9%) in Cambodia), 
North Africa (12.2% (7.7–18.0%) in Tunisia; 51.3% (44.7–57.6%) 
in Sudan) and throughout sub-Saharan Africa. Overall, in 2018, 
national EBF prevalence varied by as much as 39.2 times across 
all LMICs, ranging from 2.2% (1.1–4.0%) in Chad (Western 
sub-Saharan Africa) to 87.7% (76.9–94.2%) in Rwanda (Eastern 
sub-Saharan Africa).
Select LMICs made notable progress in the study period. In 2000, 
57 LMICs had <30% estimated mean EBF prevalence in at least half 
of their first-administrative-level units (henceforth ‘provinces’); by 
2018, eight of these countries had increased mean EBF prevalence 
to come close to the original WHO GNT of 50% EBF prevalence, 
with at least 45% EBF in most provinces: Cambodia (88.2%; 30 of 
34 provinces), Democratic Republic of the Congo (DRC; 69.2%; 18 
of 26), Guinea-Bissau (77.8%; 7 of 9), Lesotho (100.0%; 10 of 10), 
Liberia (80.0%; 12 of 15), Sudan (88.9%; 16 of 18) and Turkmenistan 
(66.7%; 4 of 6). For example, Kâmpóng Chhnang province in cen-
tral Cambodia (19.5% (14.0–26.3%) in 2000; 63.4% (47.5–77.8%) 
in 2018) and West Kurdufan state in southern Sudan (13.4% (10.4–
17.2%) in 2000; 51.9% (40.6–63.0%) in 2018) both experienced 
large gains. Overall, 34 LMICs had at least one province that made 
similar gains from <30% to ≥45% EBF prevalence (45.1%; 296 of 
656 provinces across these 34 LMICs).
To compare trends and prevalence levels, we overlaid the 
highest and lowest population-weighted deciles of EBF at the 
second-administrative level (henceforth ‘district’) to the highest 
and lowest deciles of annualized rates of change (AROC) (Fig. 1c). 
Along with having some of the lowest levels of EBF practice in 2000 
and 2018, Chad, Suriname, Somalia and Brazil also had among 
the highest rates of annualized decline in EBF during the study 
period. Districts in Niger, Nigeria, Gabon, Yemen, Tunisia, the 
Dominican Republic, southern Thailand and central Philippines 
also had among the lowest EBF prevalence levels in both 2000 
and 2018; even despite some of the highest rates of EBF increase 
in southern Vietnam and northeastern Thailand, EBF remained 
among the lowest levels in these districts in both years (Fig. 1c). 
Districts throughout much of Peru, southeastern Bolivia, eastern 
Brazil, Ethiopia, Uganda, Rwanda, Burundi, India, Nepal, Mongolia 
and the Philippines had among the highest prevalence levels in 
both years; as did select districts in Guatemala, Zambia, Malawi, 
Eritrea, Afghanistan, Pakistan and Indonesia. Districts scat-
tered throughout Guatemala, the DRC, northern Liberia, north-
ern Ghana, Eritrea, western Tanzania, Zambia, Malawi, Lesotho, 
Bangladesh and Cambodia had among the highest levels for the 
year 2018, as did select districts in western Honduras, eastern and 
western Sudan and northern Laos. Districts with some of the high-
est rates of annualized increase in EBF were located in southern 
Sierra Leone, central Côte d’Ivoire, southern Burkina Faso, cen-
tral Niger, central Nigeria, Sudan, eastern Ethiopia, DRC, Angola, 
Namibia, South Africa, northern Mozambique, central Kenya, 
Turkmenistan, western Kyrgyzstan, Myanmar, northern Thailand, 
southern Laos and southern Vietnam. In contrast, the highest 
rates of annualized decline in EBF were seen in eastern Honduras, 
Colombia, Brazil, eastern Bolivia, eastern Zambia, eastern Ghana, 
eastern Niger, central Nigeria, central Mozambique, central 
Madagascar, central Afghanistan and Pakistan. The Philippines and 
Brazil both had among the best-performing and worst-performing 
districts for both years in regard to prevalence and Niger, Nigeria 
and Mozambique had districts among the highest and lowest rates 
of annualized change.
By mapping AROC from 2000 to 2018, we show where and to 
what degree EBF practices have increased or decreased on aver-
age over the study period (Fig. 1d). Most district-level units across 
LMICs experienced increases in estimated mean prevalence of EBF 
over the study period (62.6%; 15,379 of 24,556 districts), while over 
a third experienced decreases 37.2% (9,137 of 24,556 districts). 
Overall, 28 LMICs experienced annualized increases in mean EBF 
prevalence in all districts; 25 LMICs had >2.5% annualized increase 
in all districts, including Bangladesh, Cambodia, Botswana, Liberia 
and Lesotho (Supplementary Table 8a). Sudan, Zimbabwe, South 
Africa, Kenya, Myanmar and Turkmenistan were among 14 LMICs 
that experienced among the highest annualized EBF increases (>5% 
AROC) in all of their districts’ mean estimates (Supplementary 
Table 8a). In 13 LMICs, most districts had decreasing annualized 
trends in EBF practice (<0% AROC); Chad was the only LMIC 
that experienced EBF declines in all of its districts (Supplementary 
Table 8b). A large proportion (69.1%; 65 of 94) of LMICs had both 
annualized increases and decreases in EBF across their districts; 7 
(7.4%) LMICs had districts that had experienced both extremes of 
the mapped annualized increases (>5%) and decreases (≤−2.5%): 
Nigeria, Somalia, Mozambique, Niger, Thailand, the Philippines 
and India (Supplementary Table 8c).
Comparison of units with low EBF and other health conditions. 
To identify some of the highest-need provinces across LMICs, we 
compared the lowest decile of EBF prevalence in this study to the 
highest decile levels of our previously published geospatial estimates 
of stunting16, childhood diarrhoea19 and under-5-yr mortality20 and 
the lowest decile of coverage of ORS21 and access to piped water22 
(Supplementary Information section 5.5 and Supplementary Figs. 
19–23). Several provinces in Chad had among the lowest levels of 
EBF, as well as some of the highest levels of under-5-yr mortality, 
stunting and diarrhoea and some of the lowest coverage levels of 
ORS and access to piped water. Also among the lowest levels of EBF, 
select provinces in Nigeria had among the lowest ORS coverage and 
both Niger and Nigeria had provinces with low EBF prevalence and 
some of the highest child stunting and mortality rates. Yemen had 
provinces with codistribution of low EBF prevalence and high lev-
els of child diarrhoea and stunting. Somalia had several provinces 
with low EBF and high under-5-yr mortality rates, while Gabon had 
one province with among the highest childhood diarrhoea rates 
and lowest EBF prevalence. One province in Comoros and several 
provinces in Thailand had among the lowest levels of EBF as well as 
access to piped water (Supplementary Table 12).
Geographic inequalities in EBF prevalence. We calculated Gini 
coefficients as a measure of geographic inequality at the country 
level23. Our results suggest that geographic inequality in EBF preva-
lence decreased in most of the countries from 2000 to 2018 (77 of 
94) on the basis of Gini coefficients; while there were 11 countries 
in 2000 whose Gini coefficient was >0.25, only Nigeria and the 
Philippines had coefficients above 0.25 in 2018.
We quantified absolute geographic inequalities in EBF prevalence 
by calculating the absolute differences between district-level units 
with the lowest and highest prevalence in each country (method 
details in Supplementary Information section 4.4.3). Between 
2000 and 2018, absolute geographic inequalities had increased in 
over a third (38.3%; 36 of 94) of LMICs, at least doubling in eight 
countries, including Afghanistan, Jamaica, Jordan, Nepal, Niger, 
Republic of the Congo, Sierra Leone and Turkmenistan (Fig. 2). Of 
the 92.6% (88 of 94) of LMICs which had increased in EBF national 
prevalence, almost half (42.1% (37 of 88)) had also increased in 
absolute inequalities—including in Afghanistan and Republic of the 
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Congo—indicating areas left behind in overall national progress. 
While 39.3% (37 of 94) of LMICs had increased absolute inequali-
ties between districts, 12.6% (12 of 94) of LMICs decreased their 
absolute inequalities; absolute inequalities in the other 45 LMICs 
in the analysis remained relatively the same. Several countries 
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Highest in 2000 and 2018
Fig. 1 | EBF prevalence and progress (2000–2018) among infants under 6 months across LMICs. a,b, Prevalence of EBF practices at the district level in 
2000 (a) and 2018 (b). c, Overlapping population-weighted highest and lowest deciles of prevalence and weighted AROC between 2000 and 2018, at the 
district level. d, Weighted annualized percentage change in EBF prevalence between 2000 and 2018. Maps reflect administrative boundaries, land cover, 
lakes and population; grey-coloured grid cells had fewer than ten people per 1 × 1-km grid cell and were classified as ‘barren or sparsely vegetated’ or were 
not included in this analysis50–55.
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increasing their EBF prevalence, including Burundi, Cuba, Eritrea, 
Gabon, Guinea, Malawi, Mali, Rwanda, Trinidad and Tobago and 
Uganda. Absolute inequalities in EBF were at least halved in eight 
LMICs: Burundi, Chad, Cuba, Eritrea, Gambia, Guinea, Mali and 
Rwanda. Along with substantial reductions in absolute inequalities, 
Gambia also substantially increased its national EBF prevalence, 
while Guinea, Mali and Rwanda experienced marginal increases 
in national prevalence; Chad, however, had decreased EBF preva-
lence across all its district-level units. In 2018, absolute differences 
in EBF between the highest- and lowest-prevalent districts within 
countries ranged from 1.1 to 45.3 times; São Tomé and Príncipe had 
the least variation, ranging from 66.0% (29.8–90.9%) in Me-Zochi 
(São Tomé) to 67.8% (31.3–93.0%) in Pague (Príncipe), while the 
Philippines ranged from 1.5% (0.9–2.3%) in San Jose (Antique) to 
92.8% (88.6–95.9%) in Bagamanoc (Catanduanes). Most LMICs 
(60.0% (57 of 94)) had twofold or more difference in EBF between 
districts in 2000; 36.8% (35 of 94) had this difference in 2018. A 
threefold or greater difference between units was experienced in 34 
(35.8%) and 15 (15.8%) LMICs in 2000 and 2018, respectively. A six-
fold or greater difference was experienced by 14 (14.7%) LMICs in 
2000 and 4 (4.2%) LMICs in 2018—Brazil, Nigeria, the Philippines 
and Thailand.
We quantified relative inequalities by calculating the rela-
tive differences between each district-level unit and its country’s 
average for 2000 and 2018 (Supplementary Information sec-
tion 4.4.3). Overall, within-country relative inequalities in EBF 
coverage declined; 48 LMICs in 2000 and 25 LMICs in 2018 had 
district-level units that deviated by >50% from the country mean 
(Fig. 2). Throughout the study period, Belize, Egypt, Eritrea and 
Papua New Guinea demonstrated low within-country relative 
differences in EBF, whereas Myanmar, Cambodia, Laos, Ghana 
and Peru had reduced relative geographic inequalities over time 
(Fig. 3). As an example, northern districts of Myanmar positively 
deviated and southwestern districts negatively deviated by ≥30% 
from the national mean in 2000 but these within-country relative 
differences decreased to <10% from the national mean in either 
direction by 2018. Within-country relative inequalities remained 
high, however, in Comoros, Brazil, the Philippines and Guyana 
in both 2000 and 2018. In 2018, the largest relative inequalities 
were in Nigeria, Brazil, Thailand and the Philippines. In particu-
lar, Nigeria’s most negatively deviating district-level units were 
concentrated in the north and southeast, while central districts 
loomed largely above the mean in 2018 (20.1% (18.8–21.4%) 
national mean; 3.4% (1.7–5.9%) in Baure (Osun); 53.7% (41.3–
62.7%) in Ife Central (Osun)). Additionally, in Brazil, deviating 
patterns were scattered, with districts throughout much of the 
Amazon Basin in the west positively deviating from the national 
mean (for example, 80.1% (80.8–83.7) in Machadinho munici-
pality (Rondônia) in 2018) and many districts in the Brazilian 
Highlands negatively deviating from the mean (for example, 
10.7% (9.9–11.7%) in Abadia de Goiás municipality (Goiás); 
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Fig. 2 | Geographic inequalities in EBF prevalence across 94 countries for 2000 and 2018. a, Absolute inequalities: range of EBF estimates in district-level 
units within 94 LMICs. b, Relative inequalities: range of ratios of EBF estimates in district-level units relative to country means. Each dot represents a 
district-level unit. The lower bound of each bar represents the district-level unit with the lowest EBF in each country. The upper end of each bar represents 
the district-level unit with the highest EBF in each country. Thus, each bar represents the extent of geographic inequality in EBF estimated for each country. 
Bars indicating the range in 2018 are coloured according to their gBD super-region. grey bars indicate the range in EBF in 2000. The black diamond in 
each bar represents the median EBF estimated across district-level units in each country and year. A coloured bar that is shorter than its grey counterpart 
indicates that geographic inequality has narrowed. Countries are labeled by their ISO 3 codes (full country names are listed in Supplementary Table 4).
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Absolute number of children not exclusively breastfed. In 
2000, of the ~56,039,700 (51,145,700–60,940,400) infants under 
6 months in the populations across the 94 countries in our analy-
sis (according to the 2019 GBD Study24), an estimated 33,489,000 
(31,867,900–35,031,200) infants were not exclusively breastfed. In 
2018, among a population of ~57,787,200 (51,016,200–64,661,000) 
infants under 6 months in 94 LMICs24, an estimated 31,878,600 
(28,721,500–34,999,000) children were not exclusively breastfed, 
representing a 4.8% (0.1–9.9%) decrease since 2000. A compari-
son of shifts in prevalence and numbers of non-EBF children over 
the past two decades suggests that, despite some of the largest 
increases in EBF prevalence in Asia and Oceania, the bulk of the 
total number of infants not benefiting from EBF still comes from 
these regions (Fig. 4).
Four countries have more than an estimated million infants 
each that were not exclusively breastfed in 2018 (Fig. 5), account-
ing for 39.9% of the total: India (5,351,900 (4,825,700–5,904,700); 
19.1% of the total non-EBF infants), Nigeria (2,899,100 (2,850,500–
2,945,200); 10.4%), Pakistan (1,770,300 (1,653,400–1,889,400); 
6.3%) and Brazil (1,157,000 (1,116,400–1,200,800); 4.1%). Eight 
additional countries each had an estimated half-million children 
or more that were not exclusively breastfed in 2018, account-
ing for 17.4% of the total non-EBF infants: Indonesia (982,200 
(897,700–1,063,100); 3.5% of the total), the Philippines (782,100 
(658,100–893,800); 2.8%), Mexico (760,500 (699,500–813,800); 
2.7%), DRC (741,200 (623,700–848,700); 2.7%), Ethiopia (626,800 
(427,600–851,000); 2.2%), Bangladesh (609,900 (402,100–832,000); 
2.1%), Egypt (574,100 (480,700–670,500); 2.0%) and Vietnam 
(515,500 (455,800–564,800); 1.8%). Although some of these 
countries were close to achieving the original WHO GNT of 50% 
prevalence by 2018, with >45% mean national prevalence, Mexico 
has had low EBF prevalence scattered throughout its units and the 
Philippines has consistently had some of the largest subnational 
inequalities. Nigeria, Brazil and Vietnam have the dual complica-
tions of high geographic inequalities and relatively low national EBF 
prevalence (<30%).
Projected EBF prevalence in 2025 and 2030. On the basis of pre-
vious spatiotemporal historical trends and the assumption that 
recent trends will continue, we projected EBF estimates for the year 
2025 (Supplementary Fig. 17a,b) and 2030 (Fig. 6a,b). Overall, EBF 
prevalence across LMICs is expected to increase from 38.7% (28.3–
49.9%) in 2018 to 42.6% (25.6–60.5%) in 2025 and to reach 45.2% 
(23.9–67.2%) by 2030. National EBF prevalence is expected to vary 
by as much as 56.6 times across all LMICs (1.6% (0.5–3.8%) in Chad; 
87.9% (67.4–97.0%) in Rwanda) in 2025, while within-country dif-
ferences are expected to range from 1.1 to 62.9 times, with the most 
variation in the Philippines, Brazil and Nigeria (ninefold or more 
difference). By 2030, national-level prevalence is projected to vary 
by 71.3 times across LMICs (1.2 (0.3–3.7%) in Chad; 87.7% (59.9–
98.1%) in Rwanda), with subnational variation ranging from 1.1 to 
80.4 times; Brazil, the Philippines and Nigeria are expected to main-
tain a ninefold or greater difference between districts.
Our predictions for 2025 and 2030 show similar levels of EBF 
and patterns of subnational inequalities throughout LMICs as in 
2018, with a few notable exceptions. On the basis of current tra-
jectories, some of the largest projected gains are expected through-
out sub-Saharan Africa. In Guinea-Bissau, Mauritania, Sierra 
Leone, Namibia, Zimbabwe and Gambia, most districts had <50% 


























Fig. 3 | Relative geographic inequalities within countries in EBF prevalence in 2000 and 2018: comparing district-level units to the country-level 
means. a,b, Relative deviation of EBF prevalence in district-level units from the country-level EBF mean in 2000 (a) and 2018 (b). Blue indicates a positive 
deviation from the EBF country-level mean, indicating a higher EBF prevalence level. Red indicates a negative deviation from the EBF country-level mean, 
indicating a lower EBF prevalence level. Maps reflect administrative boundaries, land cover, lakes and population; grey-coloured grid cells had fewer than 
ten people per 1 × 1-km grid cell and were classified as ‘barren or sparsely vegetated’ or were not included in this analysis50–55.
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meet or exceed the original 50% EBF target in most districts in 
2025. Outside of sub-Saharan Africa, Turkmenistan, Myanmar, 
Indonesia and Kyrgyzstan are also expected to exceed the 50% EBF 
mean prevalence target in most of their districts by 2025. Projected 
declines are expected to lead to districts in 15 LMICs that had mean 
estimates of EBF of ≥50% in 2018 to drop below this threshold by 
2025; for example, Argo (Badakshan) in northeastern Afghanistan 
is expected to decrease from 52.4% (32.6–71.9%) in 2018 to 48.9% 
(17.8–60.45%) in 2025. By 2025, 33 LMICs are projected to have 
national mean EBF prevalence that meet the original WHO GNT of 
≥50%, while 16 LMICs are predicted to have mean EBF prevalence 
meeting this target in all of their province-level units; 11 LMICs are 
expected to meet this target in all of their district-level units by 2025.
By 2030, six LMICs (Burundi, Cambodia, Lesotho, Peru, 
Rwanda and Sierra Leone) are projected to have mean national EBF 
prevalence that meet the updated WHO GNT of ≥70%, while three 
LMICs (Burundi, Lesotho and Rwanda) are predicted to meet this 
target in all their province-level and district-level units. Five LMICs 
(the Philippines, India, Peru, Ghana and Bolivia) had districts that 
met the ≥70% WHO GNT in 2018 which are expected to fall below 
this threshold in 2030, such as in Sandia (Puno), Peru (70.6% (51.2–
88.4%) in 2018; 64.0% (33.8–87.1%) in 2030) and Mallig (Isabella), 
the Philippines (70.5% (54.5–83.2%) in 2018; 69.1% (38.2–90.0%) 
in 2030).
Progress towards the 2030 WHO GNT of ≥70% EBF. We mapped 
the probabilities of meeting the updated WHO GNT of ≥70% EBF by 
2018 and 2030 at various scales (Supplementary Fig. 18 and Fig. 6c). 
Across LMICs, 86.2% (81 of 94), 63.8% (60 of 94) and 52.1% (49 
of 94) had a low probability (<5%) of having achieved the updated 
WHO GNT of ≥70% EBF at the national level, in all provinces, or 
in all districts, respectively, by 2018 (Supplementary Table 10a). 
Rwanda was the only LMIC that had a high probability (>95%) of 
having already achieved the 70% target in 2018 at the national level, 
as well as the only LMIC to have had a high probability of meeting 
the target in all province-level units. No LMIC, however, had a high 
probability of meeting WHO GNT of 70% in all their district-level 
units in 2018. Across LMICs, 84.4% (20,717 of 24,556) of districts 
located in 88 LMICs had a low probability, while only 1.0% (256 of 
24,556) of districts in five LMICs had a high probability of having 
achieved the updated target of 70% by 2018. Three LMICs had dis-
tricts with both high and low probability of having met the new 70% 
target by 2018: Brazil, Peru and the Philippines.
In analysing probabilities of meeting the updated WHO GNT 
of ≥70% EBF by the year 2030, most LMICs (56.4% (53 of 94)) are 
expected to have a low probability (<5%) of nationally achieving 
this goal; 23.4% (22 of 94) and 13.8% (13 of 94) of LMICs have a 
low probability of meeting this goal in all of their province- and 
district-level units, respectively (Supplementary Table 10b). No 
LMIC has a high probability (>95%) of meeting the ≥70% target 
by 2030 at the national level or in all their province- or district-level 
units. Across LMICs, only 0.7% (177 of 24,556) of districts located 
in seven LMICs have a high probability, while 59.1% (14,518 of 
24,556) of districts in 56 LMICs have a low probability of meeting 
the ≥70% target by 2030. Extreme subnational inequalities in prob-
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Fig. 4 | Number of infants under 6 months who are not being exclusively breastfed, distributed across non-EBF prevalence in 2000 and 2018, across 
94 countries. a, Non-EBF infants under 6 months in 2000. b, Non-EBF infants under 6 months in 2018. The dotted line in the 2000 plot is the shape of 
the distribution in 2018 and the dotted line in the 2018 plot represents the distribution in 2000. Bar heights represent the total number of infants under 
6 months who were not exclusively breastfed by district-level units, with corresponding non-EBF prevalence. Bins are a width of one non-EBF infant per 
100 infants. The colour of each bar represents the global region as defined by the subset legend map. As such, the sum of heights of all bars represents the 
total number of non-EBF infants across the 94 countries.
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EBF target by 2030 are expected to occur in 3.2% (3 of 94) of LMICs: 
Brazil, the Philippines and Mongolia. See Supplementary Table 9 
and Supplementary Fig. 17 for probabilities of meeting the original 
WHO GNT of ≥50% by 2025.
Discussion
EBF practice has been known to vary by region, country and 
population25–27 but an understanding of the subnational distribu-
tion of this heterogeneity is hampered by several limitations in the 
previously available estimates. Previous studies have estimated EBF 
prevalence and interest groups such as UNICEF26 and Countdown 
to 203027 have compiled EBF datasets and country profiles; some of 
these results have been stratified by urban–rural status or wealth 
quintiles or mapped at the first-administrative level (for example, 
states, provinces). These maps and datasets, however, are lim-
ited to select countries or years and do not allow for comparisons 
across countries for each year or within countries at more detailed 










































































Fig. 5 | Number of infants under 6 months who are not being exclusively breastfed at the district level, 2000 and 2018. a,b, Number of infants under 
6 months who are not being exclusively breastfed, aggregated to district-level units in 2000 (a) and 2018 (b). c, Difference in number of infants under 
6 months who are not being exclusively breastfed between 2018 and 2000, aggregated to district-level units. Maps reflect administrative boundaries, land 
cover, lakes and population; grey-coloured grid cells had fewer than ten people per 1 × 1-km grid cell and were classified as ‘barren or sparsely vegetated’ or 
were not included in this analysis50–55.
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critical to determining where increased breastfeeding support 
efforts are needed to lead to the most improvement. This study 
maps comparable subnational estimates of EBF prevalence across 
most LMICs over an almost 20-yr period, projects these estimates to 
WHO GNT target years and quantifies within-country inequalities. 
Not only can these estimates aid tracking progress toward WHO 
GNTs but also toward the United Nation’s Sustainable Development 
Goal (SDG)28 to reduce national inequalities in health opportunities 
and outcomes, both between and within countries, by 2030.
Although EBF is considered a cost-effective intervention, it is 
not free; it requires investment of time and energy from mothers 
and support from wider networks, including their families, com-
munities, workplaces, health systems and government leadership. 
Manipulative marketing of breast-milk substitutes29,30, inadequate 
workplace support31, late or lack of attendance at antenatal care32, 
lack of skilled lactation support or breastfeeding counselling in 
health facilities11,32 and societal beliefs favouring mixed feeding11,32–34 











































































Fig. 6 | Projected prevalence for EBF for 2030 and probability of meeting the ≥70% WHo GNt by 2030. a,b, Projected EBF prevalence for 2030 at the 
national (a) and district (b) levels. c, Probability of meeting the WHO gNT of at least 70% EBF prevalence by 2030 at the district level. Dark blue indicates a 
high probability (>95% posterior probability) and dark red indicates a low probability (<5% posterior probability) of meeting the WHO gNT by 2030. Maps 
reflect administrative boundaries, land cover, lakes and population; grey-coloured grid cells had fewer than ten people per 1 × 1-km grid cell and were classified 
as ‘barren or sparsely vegetated’ or were not included in this analysis50–55.
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Breastfeeding Collective (GBC) initiative stresses the need for advo-
cacy at global, national and subnational levels to improve breast-
feeding rates for the betterment of maternal and child health and 
wellbeing36. The GBC’s Breastfeeding Advocacy Toolkit outlines 
seven key policy actions to increase breastfeeding practices, which 
are: increasing funding to support EBF and continued breastfeeding 
to 2 years; fully adopting and monitoring the International Code of 
Marketing of Breast-Milk Substitutes (‘the Code’); enacting work-
place breastfeeding policies and paid family leave; implementing 
the ‘baby-friendly’ hospital’s ‘ten steps to successful breastfeeding’; 
improving access to skilled breastfeeding counselling in health 
facilities; strengthening links between health facilities and com-
munities to support breastfeeding; and strengthening monitoring 
systems to track progress36. Inconsistent implementation of these 
policies could contribute to the between- and within-country varia-
tion we see in EBF practice across LMICs. Combined with informa-
tion on breastfeeding interventions, our mapped estimates can aid 
policy-makers in monitoring the success of breastfeeding policy and 
programme investments.
The World Bank estimates that an investment of US$4.70 per 
live newborn is needed to meet the WHO GNT for EBF by 202537,38. 
According to the Global Breastfeeding Scorecard, however, only 
five LMICs in this analysis meet or exceed estimated funding needs 
(Guinea-Bissau, Haiti, Nepal, Somalia and Timor-Leste), while 50 
spend <US$1 per live birth on breastfeeding support programmes, 
as of 201839. Aggressive marketing of breast-milk substitutes (BMS) 
disrupts mothers’ informed choices by providing misleading infor-
mation. In response to controversial marketing strategies, the World 
Health Assembly established the Code in 1981 to regulate the pro-
motion and safety of BMS and ensure the adequate nutrition of 
infants40. The Code bans point-of-sale promotion of BMS or bottles, 
distribution of free samples and misleading promotional materials 
suggesting a product’s superiority over mother’s natural milk40. In 
2018, however, only 24 of the 94 LMICs in this study had compre-
hensive Code legislation in place and 25 had no legal measures pro-
tecting consumers from aggressive BMS marketing tactics39. A study 
on global infant formulas sales showed that the steepest market 
increases were in Asia Pacific (18% increase) and Middle East and 
Africa (14% increase) regions within just 1 year (2012–2013)30; by 
2025, the infant formula industry is expected to surpass US$98 billion 
in sales41, and increase in marketing and sales will likely negatively 
affect breastfeeding42,43. Additionally, few LMICs have national poli-
cies that satisfy the International Labour Organization’s Convention 
minimum recommendations for 14 weeks of paid maternity leave 
and appropriate workplace nursing areas; Colombia, Cuba, India, 
Paraguay, Tajikistan and Vietnam are the only six LMICs in our 
analysis that fully met these recommendations in 201839. Individual 
breastfeeding counselling was reported to be implemented in all 
primary healthcare facilities in just 28 LMICs39. Of the LMICs with 
available data, at least half of births were in baby-friendly hospitals 
and maternities in only six countries (Costa Rica, Cuba, Eswatini, 
Tajikistan, Thailand and Turkmenistan)39. By subnational report-
ing, 29 LMICs in the analysis had implemented community pro-
grammes in all districts in 201839. Our estimates, combined with the 
WHO’s Breastfeeding Scorecard Data, can be used to decide where 
additional resources to support breastfeeding are most needed 
(Supplementary Information section 5.4).
Positive exemplars in EBF uptake due to policy implementa-
tion and financial investments could provide lessons learned for 
policy-makers to apply towards their countries. The 2018 Global 
Nutrition Report spotlighted Burkina Faso’s strong commitment to 
supporting breastfeeding through the rapid roll-out of a national 
infant and young feeding programme that led to all primary health-
care facilities providing counselling and 70% of districts with com-
munity programmes for breastfeeding support35. Furthermore, 
Burkina Faso passed legislation providing 14 weeks of state-funded 
maternity leave and laws prohibiting advertising breast-milk sub-
stitutes35; by our estimates, most districts experienced >5% annu-
alized increase in EBF over the modelled study period. In Nepal, 
USAID’s integrated nutrition programme combined water and 
sanitation, family planning and agricultural activities along with 
essential nutrition and breastfeeding counselling to children and 
caregivers in 42 of 77 districts and the recommended minimum 
US$4.70 per live-birth investment was met in 201835; by our esti-
mates, all districts in Nepal had annualized EBF increases between 
2000 and 2018. The USAID’s programming in Malawi worked with 
the Ministry of Health to achieve ‘baby-friendly’ status in hospi-
tals, develop a nutrition training for nurses and midwives and pro-
vide deworming and vitamin A supplementation35; these combined 
efforts may have contributed to many of Malawi’s districts being 
>50% of mean EBF prevalence in 2018. Turkmenistan’s success in 
achieving >5% annualized increase in all of its districts by 2018 may 
be attributed to the high proportion of births in baby-friendly hos-
pitals (86.9%) and community breastfeeding programmes imple-
mented in all its districts39. Gambia and Côte d’Ivoire, which had 
reduced absolute inequalities by at least a third, fared well on the 
Breastfeeding Scorecard; basic maternity provisions, as well as com-
munity programmes in all districts and counselling in all facilities 
were reported for Côte d’Ivoire and Gambia had full legal status of 
the Code, met recommended maternity leave length and all facilities 
offered counselling. Although we identified Cambodia as having 
among the highest EBF prevalence levels in 2018, and Myanmar as 
having among the highest annualized increases, and both countries 
experienced large reductions in relative inequalities, they did not 
have widespread supportive breastfeeding policies implemented, 
according to their 2018 national scorecard39. Additional local inves-
tigations are needed to document subnational policy implementa-
tion and determine associations between breastfeeding policies and 
interventions and EBF progress.
This study provides a comprehensive picture of the unmet need 
for EBF by mapping both prevalence of EBF and the absolute num-
ber of children not exclusively breastfed for their first 6 months of 
life. Our mapped estimates provide a tool to visualize subnational 
inequalities otherwise masked by national-level estimates and 
areas left behind in EBF uptake. These subnational EBF estimates 
can aid policy- and decision-makers in tracking progress towards 
the international target and in identifying where additional breast-
feeding support efforts are needed to improve child health and 
survival. Comparisons against additional health indicators could 
inform the development of more comprehensive approaches to 
improve health in populations most in need. Future research could 
compare these estimates with breastfeeding policies and interven-
tions, or lack thereof, to determine which were most successful in 
achieving increased practice of EBF and what barriers still need to 
be addressed.
Methods
Overview. For this study, we used a similar methodology to that of our previous 
work on mapping EBF prevalence in Africa14 and extended our scope to 
include all LMICs with available relevant data. LMIC status was determined by 
sociodemographic index (SDI), which indicates a country’s level of development 
on the basis of poverty, education and fertility as defined in the GBD study. Here 
we map estimates of countries that have low, low-middle or middle SDI status 
(Supplementary Table 4). We excluded several countries from our analysis despite 
low, low-middle or middle status due to lack of relevant input data (Cape Verde, 
Dominica, Djibouti, Ecuador, Grenada, Iran, Libya, Malaysia, Seychelles, Sri 
Lanka and Venezuela). This study complies with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER; http://gather-statement.org; 
Supplementary Information section 1.0).
Data. Surveys and EBF indicator data. When searching the Global Health Data 
Exchange (GHDx; http://ghdx.healthdata.org) for the keyword ‘breastfeeding’, we 
compiled an extensive geo-located dataset that includes 345 household surveys 
(including the Demographic and Health Surveys (DHS), Multiple Indicator 
Cluster Surveys (MICS) and other country-specific or multinational surveys) 
NatuRE HuMaN BEHaVIouR | VOL 5 | AUgUST 2021 | 1027–1045 | www.nature.com/nathumbehav 1035
Articles Nature HumaN BeHaviour
conducted in years 1998 to 2018 in LMICs. Of these, we assigned data from 21 
surveys conducted in years 1998 or 1999 to the year 2000 to address data scarcity. 
This dataset represents 302,435 infants aged 0–5 months (infants up to the age of 
6 months) across 94 LMICs and was geocoded to 69,179 coordinates corresponding 
to cluster-level boundaries and 67,750 subnational polygon boundaries. Across the 
94 countries in the analysis, there were 1,727 first-administrative-level boundaries 
(for example, provinces) and 24,556 second-administrative-level boundaries (for 
example, districts). Overall inclusion criteria for surveys included: conducted 
in an LMIC between 1998 and 2018; responses available at the individual level; 
contains subnational geographic identifiers (that is, GPS coordinates, cluster or 
administrative units) with survey weights for each observation; and contains 
questions and responses about child’s age and breastfeeding status. A survey 
was included if it contained questions and responses regarding whether the 
child had consumed other food or liquids besides breast-milk. We only included 
observations of children who were under 6 months at the time of the survey 
(0–5 months). See the Supplementary Information sections 2.1 and 2.2 for further 
details on exclusion and inclusion criteria.
Spatial covariates. In these analyses, we included 11 socioeconomic and 
health-related covariates identified as conceivably associated with breastfeeding 
practices: (1) travel time to the nearest settlement >50,000 inhabitants, (2) 
nighttime lightsTV, (3) populationTV, (4) number of children under 5 yr per woman 
of childbearing ageTV, (5) urban proportion of the locationTV, (6) number of people 
whose daily vitamin A needs could be met, (7) educational attainment in women 
of reproductive age (15–49-years-old)TV, (8) human development index (HDI)TV, 
(9) human immunodeficiency virus (HIV) prevalenceTV, (10) healthcare access and 
quality indexTV and (11) proportion of pregnant women who received four or more 
antenatal care visitsTV (where superscript TV indicates time-varying covariates). 
Of these, the covariates for the Healthcare Access and Quality Index44 and the 
proportion of pregnant women who received four or more antenatal care visits45 
were indexed at the national level, while all others were indexed at the subnational 
level. The spatial covariates were selected because they are factors or proxies for 
factors that previous literature has identified to be associated (not necessarily 
causally) with EBF prevalence.
Variance inflation factor46 (VIF) analysis was used to filter covariates for 
multicollinearity. We performed temporal processing for covariates that did 
not have information for every year of the modelled study period and filled in 
intervening years with the value from the nearest neighbouring year or used an 
exponential growth rate model. Detailed information on covariates can be found in 
Supplementary Table 5 and Supplementary Fig. 8.
Analysis. The technical descriptions of methods for the underlying geostatistical 
model, model validation and postestimation are consistent with those previously 
used in the geospatial modelling of EBF across Africa14.
Geostatistical model. EBF was modelled using a Bayesian geostatistical approach. 
This approach uses a hierarchical logistic regression model that is spatially and 
temporally explicit, and assumes points close in space and time and with similar 
covariate patterns will have similar levels of EBF. Using a stacked generalization 
technique, we also incorporated potential nonlinear relationships between 
covariates and EBF input data. For all model parameters and hyper-parameters, we 
used the R-INLA statistical package to approximate posterior distributions47. We 
used 1,000 draws from these approximate joint posterior distributions to calculate 
uncertainty intervals (UI), determining and reporting the 2.5th and 97.5th 
percentiles of those 1,000 draws. Further details on methodology can be found in 
Supplementary Information section 4.0. Extended Data Fig. 1 provides an overview 
of analytical processing steps involved in the analysis.
Model validation. We used fivefold cross validation to validate models, as 
summarized below. Complete methods used for validation and related results are 
available in the Supplementary Information. First, we combined randomized sets 
of cluster-level data points at the first-administrative level to create holdout sets. 
Afterwards, we fit the geostatistical model five times, sequentially excluding each 
of the five groups of data, and provided out-of-sample predictions that correspond 
to all included surveys in the analysis. We summarized the performance of the 
model using 95% data coverage within prediction intervals, correlation between 
predictions and observed data and the mean error (a measure of bias) and 
root-mean-square error (a measure of total variance). Model estimates were also 
compared with other existing estimates, as possible.
Postestimation. To estimate EBF prevalence at various levels (province, district 
and country), we aggregated each of the 1,000 draws of coverage at the 5 × 5-km 
grid-cell level, weighted by population. We preformed posthoc calibration of our 
estimates to the GBD 2019 estimates12. This allowed us to include data sources 
outside of the scope of our geospatial modelling framework. On the basis of 
the estimates, we calculated absolute differences between lowest and highest 
administrative units and relative differences between a country’s average and 
each administrative unit in that country to quantify geographic inequality. We 
performed a simple projection calculation by comparing the estimated rates of 
EBF improvement between 2000 and 2018 with the improvements needed between 
2018 and 2030 to meet the WHO GNT (Supplementary Information section 4.4.4). 
The national time series and aggregated input data in our estimates can be found in 
Extended Data Fig. 2.
Modelling limitations. The modelling limitations in this work are consistent with 
those previously described in the geospatial modelling of EBF across Africa14.
While we have attempted to propagate uncertainty from various sources 
through the different modelling stages, there are some sources of uncertainty that 
have not been propagated. In particular, it was not computationally feasible to 
propagate uncertainty from the submodels in stacking through the geostatistical 
model. Similarly, although the WorldPop population raster is also composed of 
estimates associated with some uncertainty, this uncertainty is difficult to quantify 
and not currently reported and we were unable to propagate this uncertainty into 
our estimates of EBF prevalence for administrative units that were created using 
population-weighted averages of grid-cell estimates. Model fitting was carried out 
using an integrated nested Laplace approximation to the posterior distribution, 
as implemented in the R-INLA package47. Prediction from fitted models was 
subsequently carried out using the inla.posterior.sample() function, which 
generates samples from the approximated posterior of the fitted model. Both model 
fitting and prediction thus require approximations, and these approximations may 
introduce error.
To estimate projections of EBF prevalence levels in 2025 and 2030, we used 
previous historical trends and the assumption that recent trends will continue. 
These assumptions in turn lend to modelling limitations, as we were not able to 
project underlying drivers of changes in EBF, such as increasing urbanization or 
changes in population35,48,49, and the certainty of our estimates and projections were 
critically dependent on data quality and availability. Availability of relevant data 
varies both spatially and temporally across LMICs (Supplementary Figs. 1–5) and 
lack of relevant data is one of the main sources of uncertainty around our estimates 
(as seen in Extended Data Fig. 3). We have mapped EBF prevalence levels against 
the relative uncertainty of our estimates in Extended Data Fig. 3.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The information given here is mostly consistent with our previous study 
modelling EBF across Africa14. The findings of this study are supported by 
data that are available in public online repositories, data that are publicly 
available on request from the data provider and data that are not publicly 
available due to restrictions by the data provider and which were used under 
license for the current study. Details on data sources can be found on the 
GHDx website (http://ghdx.healthdata.org/lbd-publication-data-input-source
s?field_rec_ihme_publication_tid=29093), including information about the 
data provider and links to where the data can be accessed or requested (where 
available). We have also provided maps of the data included in our models in 
Supplementary Figs. 1–5. Outputs of these EBF analyses can be explored at 
various spatial levels (national, administrative and 5 × 5-km levels) through our 
customized visualization tool (https://vizhub.healthdata.org/lbd/ebf) and are 
publicly available at the GHDx (http://ghdx.healthdata.org/record/ihme-data/
global-exclusive-breastfeeding-prevalence-geospatial-estimates-2000-2019). 
Administrative boundaries were retrieved from the Database of Global 
Administrative Areas (GADM)50. Land cover was retrieved from the online Data 
Pool, courtesy of the NASA EOSDIS Land Processes Distributed Active Archive 
Center, USGS/Earth Resources Observation and Science Center, Sioux Falls, South 
Dakota51. Lakes were retrieved from the Global Lakes and Wetlands Database, 
courtesy of the World Wildlife Fund and the Center for Environmental Systems 
Research, University of Kassel52. Populations were retrieved from WorldPop53. All 
maps in this study were produced using ArcGIS Desktop 10.6.
Code availability
All codes used for these analyses are publicly available online at https://github.com/
ihmeuw/lbd/tree/ebf-lmic-2021.
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Extended Data Fig. 1 | analytic process overview. The process used to produce EBF prevalence estimates across LMICs involved three main parts. In the 
data-processing steps (orange), data were identified, extracted, and prepared for use in the models. In the modelling phase (yellow), we used these data 
and covariates in stacked generalization ensemble models and spatiotemporal gaussian process models for each EBF indicator. In post-processing (green), 
we calibrated the prevalence estimates to match the gBD 201912 study estimates and aggregated the estimates to the first- and second-administrative 
levels in each country.
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Extended Data Fig. 2 | National time series plots and aggregated input data. National time series plots of the post-gBD calibration final estimates 
by country during 2000–2018. Uncertainty ranges are presented in grey, and aggregated input data are classified by survey series (purple for 
country-specific, green for DHS, and yellow for MICS surveys), data type (square for polygon, circle for point data), and whether the survey is nationally or 
subnationally representative).
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Extended Data Fig. 3 | Relative uncertainty in EBF estimates for 2018. Relative uncertainty in second-administrative-level estimates compared with mean 
estimated EBF prevalence in each second-administrative-level unit for 2018. Mean prevalence and relative uncertainty are split into population-weighted 
quartiles. These cut-off points for relative uncertainty (calculated as the absolute range of the uncertainty intervals divided by the estimate) are 0.684 
(25th percentile), 0.916 (50th percentile), and 1.271 (75th percentile), respectively. The cut-off points for EBF prevalence are 25.8% (25th percentile), 
35.4% (50th percentile), and 49.4% (75th percentile), respectively. Units in which our estimates are more uncertain are coloured with a scale of 
increasing blue hue, whereas areas in which the mean estimates of EBF are low are coloured with a scale of increasing red hue. Purple areas have low, but 
uncertain, estimates of EBF. White areas have high EBF estimates that are fairly certain. Relative uncertainty is defined as the ratio of the width of the 95% 
uncertainty interval to mean estimate. Maps reflect administrative boundaries, land cover, lakes, and population; grey-coloured grid cells had fewer than 
ten people per 1 × 1-km grid cell and were classified as ‘barren or sparsely vegetated’, or were not included in this analysis50–55.
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